{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:17:44Z","timestamp":1765541864408,"version":"3.48.0"},"reference-count":15,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clomiphene citrate is a first-line drug for the induction of ovulation in infertility cases. Leukocytoclastic vasculitis (LCV) is an extremely rare serious adverse drug reaction to clomiphene. We report here the case of a 30-year-old Indian female patient who presented with generalized petechiae and palpable purpura without fever and sparing the mucosa, temporally related to clomiphene intake and consistent with LCV histologically. Clomiphene was stopped and the patient was treated symptomatically with prednisolone 40 mg\/day, oral levocetirizine 5 mg twice daily, and emollients and calamine lotion topically. The patient improved over 3\u20134 weeks. The prednisolone dose was tapered weekly and withdrawn gradually. To date, drug-induced LCV has not been previously reported with clomiphene. Although rare, clomiphene could be considered a potential cause of drug-induced cutaneous LCV in the differential diagnosis of erythematosus rash with non-blanching petechiae and purpura.<\/jats:p>","DOI":"10.1515\/jbcpp-2018-0183","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T05:02:15Z","timestamp":1564030935000},"source":"Crossref","is-referenced-by-count":2,"title":["A rare case of clomiphene-induced leukocytoclastic vasculitis"],"prefix":"10.1515","volume":"30","author":[{"given":"Yashika","family":"Garg","sequence":"first","affiliation":[{"name":"ESIC Dental College and Hospital , Department of Pharmacology , New Delhi , India"},{"name":"Vardhman Mahavir Medical College and Safdarjung Hospital , Department of Pharmacology , New Delhi , India"},{"name":"Apartment No. 174, Agroha Kunj Apartments, Rohini Sector 13 New Delhi 110085 , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourabh","family":"Jain","sequence":"additional","affiliation":[{"name":"All India Institute of Medical Sciences (AIIMS) , Department of Dermatology , Bhopal , India"},{"name":"Vardhman Mahavir Medical College and Safdarjung Hospital , Department of Dermatology , New Delhi , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Kumar","sequence":"additional","affiliation":[{"name":"Vardhman Mahavir Medical College and Safdarjung Hospital , Department of Pharmacology , New Delhi , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_001_w2aab3b7c64b1b6b1ab2b1b1Aa","unstructured":"Schimmer BP, Parker KL. Contraception and pharmacotherapy of obstetrical and gynaecological disorders. In: Brunton LL, Chabner BA, Knollmann BJ, eds. Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011:1841\u201343."},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_002_w2aab3b7c64b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239\u201345.","DOI":"10.1038\/clpt.1981.154"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_003_w2aab3b7c64b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1\u201311.","DOI":"10.1002\/art.37715"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_004_w2aab3b7c64b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Gota CE, Calabrese LH. Diagnosis and treatment of cutaneous leukocytoclastic vasculitis. Int J Clin Rheumatol 2013;8:49\u201360.","DOI":"10.2217\/ijr.12.79"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_005_w2aab3b7c64b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Bondalapati S, Vanamali DR, Rampure D, Rama Rao S. Isoniazid induced cutaneous leukocytoclastic vasculitis in extra pulmonary tuberculosis (Pott\u2019s spine): a case report. J Clin Diagn Res 2014;8:MD03\u20135.","DOI":"10.7860\/JCDR\/2014\/9000.4688"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_006_w2aab3b7c64b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Cakiter AU, Kucuk OS, Ozkaya DB, Topukcu B, Onsun N. Demographic characteristics, aetiology, and assessment of treatment options in leukocytoclastic vasculitis. Postepy Dermatol Alergol 2017;34:104\u20139.","DOI":"10.5114\/ada.2017.67071"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_007_w2aab3b7c64b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Ali N, Karia N, Goldhahn R. Cefazolin as a cause of leukocytoclastic vasculitis. Clin Case Rep 2017;5:1051\u20133.","DOI":"10.1002\/ccr3.992"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_008_w2aab3b7c64b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Singh G, Hodgson T, Clarke DE. Leukocytoclastic vasculitis secondary to pyridostigmine (mestinon): report of a possible first case. Perm J. 2017;21:15\u2013240.","DOI":"10.7812\/TPP\/15-240"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_009_w2aab3b7c64b1b6b1ab2b1b9Aa","unstructured":"Sneller MC, Langford CA, Fauci AS. The vasculitis syndromes. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison\u2019s principles of internal medicine, 16th ed. New York: McGraw-Hill, 2005:2002\u201314."},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_010_w2aab3b7c64b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Gupta M. Levetiracetam-induced leukocytoclastic vasculitis. Indian J Pharmacol. 2017;49:124\u20136.","DOI":"10.4103\/0253-7613.201020"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_011_w2aab3b7c64b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Bahrami S, Malone JC, Webb KG, Callen JP. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol 2006;14:155\u201361.","DOI":"10.1001\/archderm.142.2.155"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_012_w2aab3b7c64b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Shetty RK, Madken M, Naha K, Vivek G. Leucocytoclastic vasculitis as a late complication of clopidogrel therapy. BMJ Case Rep 2013; pii: bcr2012007861. doi: 10.1136\/bcr-2012-007861.","DOI":"10.1136\/bcr-2012-007861"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_013_w2aab3b7c64b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Kapoor KG, Bekaii-Saab T. Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis. Intern Med J 2008;38:281\u201383.","DOI":"10.1111\/j.1445-5994.2008.01646.x"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_014_w2aab3b7c64b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Salem CB, Hmouda H, Slim R, Denguezli M, Belajouza C, Bouraoui K. Rare case of metformin-induced leukocytoclastic vasculitis. Ann Pharmacother 2006;40:1685\u201387.","DOI":"10.1345\/aph.1H155"},{"key":"2025121209204279382_j_jbcpp-2018-0183_ref_015_w2aab3b7c64b1b6b1ab2b1c15Aa","unstructured":"Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-\u03b1 blocking agents. J Rheumatol 2004;31:1955\u201358."}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jbcpp.2019.30.issue-4\/jbcpp-2018-0183\/jbcpp-2018-0183.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2018-0183\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2018-0183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:14:17Z","timestamp":1765541657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2018-0183\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,7,10]]},"published-print":{"date-parts":[[2019,7,26]]}},"alternative-id":["10.1515\/jbcpp-2018-0183"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2018-0183","relation":{},"ISSN":["2191-0286","0792-6855"],"issn-type":[{"type":"electronic","value":"2191-0286"},{"type":"print","value":"0792-6855"}],"subject":[],"published":{"date-parts":[[2019,7,1]]},"article-number":"20180183"}}